Phase II Trial of EPOCH and Rituxan Combined Therapy in Patients With Refractory or Relapsed CD20 Positive Intermediate Grade B-Cell Non-Hodgkin's Lymphoma
OBJECTIVES: I. Determine the response rate in patients with refractory or recurrent CD20+
intermediate grade B-cell non-Hodgkin's lymphoma treated with rituximab followed by
etoposide, vincristine, doxorubicin, cyclophosphamide, and prednisone (EPOCH). II. Determine
the toxicity of the regimen in these patients.
OUTLINE: This is a multicenter study. Patients receive rituximab IV over 4-10 hours on day 1
followed by etoposide, vincristine, and doxorubicin IV continuously on days 4-7,
cyclophosphamide IV over 5-30 minutes on day 8 and oral prednisone on days 4-8. Patients
also receive sargramostim (GM-CSF) subcutaneously beginning on day 9 until blood counts
recover. Treatment repeats every 21 days for a maximum of 8 courses in the absence of
disease progression or unacceptable toxicity.
PROJECTED ACCRUAL: Approximately 30 patients will be accrued for this study.
Primary Purpose: Treatment
Sein Aung, MD
Harry & Jeanette Weinberg Cancer Institute at Franklin Square Hospital Center
United States: Federal Government
|Franklin Square Hospital Center||Baltimore, Maryland 21237|
|Washington Cancer Institute||Washington, District of Columbia 20010|